-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師總結如下：FLS第一季業績超出預期，調整後每股收益為0.85美元（年成長18.1%），比市場普遍預期高出0.05美元。業績超預期主要得益於利潤率持續提升230個基點至15.1%，這得益於有效的定價策略和80/20效率提升計畫。然而，受中東市場不利因素影響，總銷售額下降了6.7%。訂單結構向利潤率較高的售後服務領域轉變，呈現正面趨勢；售後服務訂單僅下降1.2%至6.8億美元，而原始設備訂單下降13%至4.68億美元。此外，FLS獲得了超過1.1億美元的核電訂單，延續了其在這個戰略性長週期市場的良好發展勢頭。管理層重申了其2026財年全年調整後每股收益預期為4.00美元至4.20美元。該公司也將有機銷售成長預期從先前的1%至3%上調至-1%至+2%。美伊衝突導致訂單減少約5,000萬美元，銷售額減少2,500萬美元，最終造成營業收入減少900萬美元。然而，關稅意外回升支撐了業績指引的重申。
Related Articles
Asia
Electro Optic Systems Reports Contract Backlog Growth as of March 31
Electro Optic Systems Holdings (ASX:EOS) reported a contract backlog of AU$518 million as of March 31, up 13% from the end of 2025, according to a Thursday filing with the Australian bourse.The company closed the March quarter with unrestricted cash holdings of AU$95.1 million, representing a decrease of AU$11.8 million from the end of 2025, per the filing.
$ASX:EOS
Asia
Regis Healthcare Expects Fiscal 2026 Underlying EBITDA at Top End of Guidance
Regis Healthcare (ASX:REG) said it expects fiscal 2026 underlying earnings before interest, taxes, depreciation, and amortization (EBITDA) of about AU$135 million, at the top end of guidance, according to a Thursday Australian bourse filing.Occupancy across mature homes averaged about 96% in the fiscal third quarter, per the filing.The company said it generated net refundable accommodation deposit (RAD) cash inflows of AU$44.5 million in the third quarter, taking the total net RAD cash inflows for the year to date to AU$223 million.As resident turnover occurs, the progressive repricing of existing paid-up RADs to current advertised room prices is expected to generate net operating cash inflows of about AU$400 million over time while also increasing RAD retention earnings, the company added.
$ASX:REG
Research
Research Alert: CFRA Keeps Hold Opinion On Shares Of Mondelez International
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target price of $63, raised $1, reflects a 19x multiple of projected 2027 EPS, in line with MDLZ's historical forward P/E average. We raise our 2026 EPS estimate by $0.06 to $3.08, but cut 2027's by $0.11 to $3.32. We continue to see headwinds related to chocolate and biscuits divisions, though favorable forex has been helping to a degree. MDLZ highlighted plans to stimulate growth with more promotional activity, which could boost revenues (we see an acceleration in revenues in 2027), but may come with the trade-off of narrower margins. We note that cost-saving efforts can also contribute to staving off some of the margin pressure. MDLZ is largely hedged on its cocoa input costs for 2026 but less so in 2027. Thus, if the substantial rise in cocoa pricing in 2025 does not reemerge, it should help the bottom line in 2027 as cost pressures should ease. Share buybacks have also contributed to EPS, and we note that Q1 2026 share count was down 1.5% from one year earlier.
$MDLZ